Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises $122 million; and more
May 14, 2026 10:42 AM EDT
A Series A, B and an IPO; Cabaletta reports CAR-T results
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Confirm Endpoints as a trusted biopharma news source
CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
Create Medicines raises $122M to bolster in vivo CAR-T therapies
BeOne wins FDA approval in lymphoma race
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
Astellas treatment offers new hope to a devastated rare disease community
Integrated CDO capabilities reduce early development complexity
Eisai's slow push toward blockbuster Leqembi sales gains steam with $900M forecast
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates…
The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
It’s a crucial moment for the cell and gene therapy field. At the American Society of Gene & Cell Therapy’s annual meeting,…
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close…
